Erkinjuntti T., Kurz A., Gauthier S., Bullock R., Lilienfeld S., Damaraju C. V. (2002). Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial, Lancet, 359(9314), 1283-90.

Feldman H., Gauthier S., Hecker J., Vellas B., Subbiah P., Whalen E., et al. (2002). The efficacy and safety of donepezil in patients with moderate to severe Alzheimer's disease, Res Pract Alzheimer Dis, 6, 302-307.

Ferris S., Gauthier S. (2002). Cognitive Outcome Measures in Vascular Dementia . Dans Erkinjuntti T. & Gauthier S. (Éds.) , Vascular Cognitive Impairment (pp. 395-400). Martin Dunitz Ltd.

Gauthier S. (2002). Diagnostic instruments to assess functional Impairment . Dans Qizilbash N., Schneider L., Brodaty H., Tariot P., Kaye J., Chui H., Erkinjuntti T. & Qizilbash N. (Éds.) , Evidence-based dementia practice (pp. 101-105). Blackwell Science Ltd.

Gauthier S. (2002). Current and future therapeutic strategies for Alzheimer's disease and related dementias, Expert Rev Neurother, 2(3), 277-8.

Gauthier S. (2002). Advances in the pharmacotherapy of Alzheimer's disease, CMAJ, 166(5), 616-23.

Gauthier S. (2002). Clinical aspects . Dans Mulligan R., Van der Linden M., Juillerat A.-C. & Mulligan R. (Éds.) , The clinical management of early Alzheimer's disease : a handbook . Erlbaum.

Gauthier S., Feldman H., Hecker J., Vellas B., Ames D., Subbiah P., Whalen E., Emir B. (2002). Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease, Int Psychogeriatr, 14(4), 389-404.

Gauthier S., Feldman H., Hecker J., Vellas B., Emir B., Subbiah P. (2002). Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease, Curr Med Res Opin, 18(6), 347-54.

Gauthier S., Grundman M. (2002). Alzheimer's disease: trial designs to establish disease modification . Dans Gauthier S. & Cummings J. L. (Éds.) , Alzheimer's Disease and Related Disorders Annual (pp. 77-85). Martin Dunitz Ltd.

Gauthier S., Gélinas I. (2002). Evaluation of daily activities in vascular cognitive impairment . Dans Erkunjutti T. & Gauthier S. (Éds.) , Vascular Cognitive Impairment (pp. 411-416). Martin Dunitz Ltd.

Geiger J. D., Legace-Wiens P., , Quirion R. (2002). Creatine and Gingko Biloba Use in Sports and Health: A Knowledge Utilization Approach . Dans Mattson M. P. (Éd.) , Diet-Brain Connections: Impact on Memory, Mood, Aging and Disease (pp. 135-157). Kluwer Academic Publishers.

Joober R., Gauthier S., Lal S., Bloom D., Lalonde P., Rouleau G., Benkelfat C., Labelle A. (2002). Catechol-O-methyltransferase Val-108/158-Met gene variants associated with performance on the Wisconsin Card Sorting Test, Arch Gen Psychiatry, 59(7), 662-3.

Kask A., Harro J., von Horsten S., Redrobe J. P., Dumont Y., Quirion R. (2002). The neurocircuitry and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y, Neurosci Biobehav Rev, 26(3), 259-83.

Law A., O'Donnell J., Gauthier S., Quirion R. (2002). Neuronal and inducible nitric oxide synthase expressions and activities in the hippocampi and cortices of young adult, aged cognitively unimpaired, and impaired Long-Evans rats, Neuroscience, 112(2), 267-75.

Lupien S. J., Wilkinson C. W., Briere S., Menard C., Ng Ying Kin N. M., Nair N. (2002). The modulatory effects of corticosteroids on cognition: studies in young human populations, Psychoneuroendocrinology, 27(3), 401-16.

Lupien S. J., Wilkinson C. W., Briere S., Ng Ying Kin N. M., Meaney M., Nair N. (2002). Acute modulation of aged human memory by pharmacological manipulation of glucocorticoids, J Clin Endocrinol Metab, 87(8), 3798-807.

Ma W., Quirion R. (2002). Partial sciatic nerve ligation induces increase in the phosphorylation of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) in astrocytes in the lumbar spinal dorsal horn and the gracile nucleus, Pain, 99(1-2), 175-84.

Mennicken F., Chabot J. G., Quirion R. (2002). Systemic administration of kainic acid in adult rat stimulates expression of the chemokine receptor CCR5 in the forebrain, Glia, 37(2), 124-38.

Mollereau C., Mazarguil H., Marcus D., Quelven I., Kotani M., Lannoy V., Dumont Y., Quirion R., Detheux M., Parmentier M., Zajac J. M. (2002). Pharmacological characterization of human NPFF(1) and NPFF(2) receptors expressed in CHO cells by using NPY Y(1) receptor antagonists, Eur J Pharmacol, 451(3), 245-56.